A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This observational study will assess the compliance and persistence of patients, real life
efficacy and safety of intravenously quarterly administered 3 mg ibandronate [Bonviva/Boniva]
in comparison to oral alendronate generics in female patients with post-menopausal
osteoporosis. The anticipated time of assessment is 12 months. The target sample size is
5000-7000 patients.